CM
CBAY

Crestline Management’s Cymabay Therapeutics CBAY Stock Holding History

Crestline Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-104,392
Closed -$841K – 213
2017
Q3 		$841K Buy
+104,392
New +$706K 0.12% 107

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Crestline Management's CBAY Position: Q4 2017 in Review

Crestline Management sold out of Cymabay Therapeutics (CBAY) in Q4 2017, closing a stake of 104,392 shares — an estimated $841K sold.

Crestline Management first reported a position in CBAY in Q3 2017 and held it in 1 quarter. The position peaked at $841K in Q3 2017. 80 funds tracked by Wall St. Rank hold CBAY as of Q4 2017.

  • Crestline Management reported no remaining Cymabay Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Crestline Management sold 104,392 Cymabay Therapeutics shares in Q4 2017, an estimated $841K.
  • Crestline Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 1 quarter.
  • Crestline Management's Cymabay Therapeutics position peaked at $841K in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2017.

Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.